Lead author and year	Study design	Population	Intervention (imatinib dose given daily)	Results
Hinchcliff ME. 2016	Case study	1 female (F) with an 8-month history of diffuse cutaneous systemic sclerosis (dcSSc)	400mg	Severe adverse events (AEs)
Pope J. 2014	Early phase proof of concept trial	10 with dcSSc.	9 given 400mg, 1 placebo	Poor drug tolerability
Prey S. 2012	Double blind RCT	28 with SSc	15 given 400mg, 13 placebo	No improvement
Khanna D. 2011	Phase I/IIa pilot trial	20 with SSc	Up to 600mg	AEs present
Pope J. 2011	Double blind RCT	10 with SSc.	9 given 400mg, 1 placebo	No improvement, AEs present
Gordon J. 2014	Open label, single arm, extension phase clinical trial	17 with average disease duration of 3.5 years	100-400mg	↓ modified Rodnan skin score (mRSS)
Fraticelli P. 2014	Phase II pilot trial	30 with SSc	200mg	↑ lung function
Guo L. 2012	Case series	6 F, Chinese pts with SSc	200mg	↓ mRSS and ↑ lung function
Divekar AA. 2011	Single centre, open-label study	15 with SSc	100mg up to 600mg/day	↑ lung function
Spiera RF. 2011	1-year, phase IIa, single-arm, open-label clinical trial	30 with dcSSc	400mg	↓ mRSS and ↑ lung function
Freyhaus H. 2009	Case report	58yo F	400mg	↑ lung function
Chung L. 2009	Case report	2 with early dcSSc	200mg	↓ mRSS and ↑ lung function
Van Daele PL. 2008	Case report	69yo F	400mg	↓ mRSS and ↑ lung function
P. P. Sfikakis. 2008	Case report	24yo F	400mg	↓ mRSS and ↑ lung function